Evidence map›Paper›PMID 37474181›Full record

ArticleBMJ open2023

Alanyl-glutamine supplementation for

Cirle A Warren, Jae Hyun Shin, Ekta N Bansal, Deiziane V D S Costa, Xin Qun Wang, Martin Wu, Jonathan R Swann, Brian W Behm, Paul V Targonski, Laurie Archbald-Pannone

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04305769 (Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04305769 phase2recruitingnot on this map

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: a Randomized, Double-blind, Placebo-controlled Trial

TypeinterventionalSponsorUniversity of VirginiaRan2021 to 2027Enrolled260ConditionsClostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile ColitisArmsAlanyl-glutamine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Cirle A WarrenDepartment of Medicine, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA ca6t@virginia.edu.ORCID 0000-0002-4417-0445
Jae Hyun ShinDepartment of Medicine, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Ekta N BansalDepartment of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.
Deiziane V D S CostaDepartment of Medicine, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Xin Qun WangDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA.
Martin WuDepartment of Biology, University of Virginia College and Graduate School of Arts and Sciences, Charlottesville, VA, USA.
Jonathan R SwannSchool of Human Development and Health, University of Southampton Faculty of Medicine, Southampton, UK.
Brian W BehmDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Virginia School of Medicine, Charlottesville, VA, USA.
Paul V TargonskiDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA.
Laurie Archbald-PannoneDepartment of Medicine, Division of General, Geriatric, Palliative & Hospital Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
University of Virginia · USCarilion Clinic · USUniversity of Southampton · GBVirginia College · US

Funding

Alanyl-glutamine supplementation of standard treatment for C. difficile infectionR01AI145322 · NIAID · UNIVERSITY OF VIRGINIA · PI WARREN, CIRLE ALCANTARA · 2020 to 2024
$4.0M
Aging and Clostridium difficile infection: interplay of microbiota and host responseK08AG064151 · NIA · UNIVERSITY OF VIRGINIA · PI SHIN, JAE HYUN · 2019 to 2023
$801k
NIAID NIH HHS R01 AI145322NIA NIH HHS K08 AG064151
6 · The paper itself

Abstract

introductionMETHODS AND ANALYSIS: This study is a randomised, placebo-controlled, double-blind, phase II clinical trial. The trial is designed to determine optimal dose and safety of oral AQ at 4, 24 and 44 g doses administered daily for 10 days concurrent with standard treatment of non-severe or severe uncomplicated CDI in persons age 18 and older. The primary outcome of interest is CDI recurrence during 60 days post-treatment follow-up, with the secondary outcome of mortality during 60 days post-treatment follow-up. Exploratory analysis will be done to determine the impact of AQ supplementation on intestinal and systemic inflammation, as well as intestinal microbial and metabolic profiles. ETHICS AND DISSEMINATION: The study has received University of Virginia Institutional Review Board approval (HSR200046, Protocol v9, April 2023). Findings will be disseminated via conference presentations, lectures and peer-reviewed publications. TRIAL REGISTRATION NUMBER: NCT04305769.

Indexed as

Clostridioides difficileClostridium InfectionsAdolescentAdultClinical Trials, Phase II as TopicDietary SupplementsDipeptidesDouble-Blind MethodHumansInflammationNeoplasm Recurrence, LocalRandomized Controlled Trials as TopicTreatment OutcomealanylglutamineDipeptidesclinical trialsgastroenterologygastrointestinal infectionsinfectious diseasesrandomized controlled trial

Identifiers

PMID37474181
PMCPMC10357635
OpenAlexW4384925449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.